LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sentinel Diagnostics Develops Ready-To-Use Real-Time PCR Mix for Detection of Novel Coronavirus

By LabMedica International staff writers
Posted on 18 Mar 2020
Image: STAT-NAT® COVID-19 Assay (Photo courtesy of Sentinel Diagnostics)
Image: STAT-NAT® COVID-19 Assay (Photo courtesy of Sentinel Diagnostics)
Sentinel Diagnostics (Milan, Italy) has announced that it has developed a ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease (COVID-19). Sentinel has developed two kits in collaboration with the most important hospital lab for the detection and treatment of coronavirus in Italy.

Sentinel is focused on the development and production of in vitro diagnostics (IVD) for the most advanced clinical chemistry, immunochemistry and molecular diagnostics platforms. Besides its wide product portfolio in clinical chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the last 12 years, the company has grown in the molecular diagnostics sector and has developed the proprietary technology STAT-NAT®, able to stabilize the activity of PCR mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.

Sentinel’s STAT-NAT® COVID-19 assay is a freeze-dried ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease in human respiratory tract specimens in about 90 minutes. The company has developed two versions of this kit, which follow two international protocols for the highest sensitivity and specificity. STAT-NAT® COVID-19 HK kit is based on the Hong Kong protocol, while STAT-NAT® COVID-19 B assay follows the Berlin protocol. Both these kits are validated on the most common PCR instruments and have been tested on human respiratory tract specimens found positive.

“The R&D NAT team has developed and tested the COVID-19 assay by working side by side with one of the reference hospital labs for the detection and treatment of coronavirus in Italy” said Maurizio Gramegna, Chief Technology Officer at Sentinel Diagnostics. “Both STAT-NAT® COVID-19 HK and B are compliant with the international protocols and are able to detect the relevant genetic variants of Coronavirus COVID-19. We are always in touch with KOLs, in order to keep the assays up to date and even update them in case of any virus mutation.”

Related Links:
Sentinel Diagnostics

Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more